Product
DEC-205/NY-ESO-1 Fusion Protein CDX-1401
Aliases
CDX-1401
2 clinical trials
9 indications
Indication
Platinum-Resistant Ovarian CarcinomaIndication
Recurrent Fallopian Tube CarcinomaIndication
Recurrent Ovarian CarcinomaIndication
Recurrent Primary Peritoneal CarcinomaIndication
fallopian tube carcinomaIndication
Ovarian CancerIndication
Primary Peritoneal CarcinomaClinical trial
A Randomized Phase 2 Trial of Atezolizumab (MPDL3280A), SGI-110 and CDX-1401 Vaccine in Recurrent Ovarian CancerStatus: Active (not recruiting), Estimated PCD: 2025-03-31
Clinical trial
A Phase I/IIb Study of DEC205mAb-NY-ESO-1 Fusion Protein (CDX-1401) Given With Adjuvant Poly-ICLC in Combination With INCB024360 for Patients in Remission With Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma Whose Tumors Express NY-ESO-1 or LAGE-1 AntigenStatus: Completed, Estimated PCD: 2020-08-20